Suppr超能文献

通过定量体内重症联合免疫缺陷(SCID)再增殖细胞试验测定,与成人骨髓或动员的外周血相比,原始人类造血细胞在脐带血中更为富集。

Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay.

作者信息

Wang J C, Doedens M, Dick J E

机构信息

Department of Genetics, Research Institute, Hospital for Sick Children, University of Toronto, Canada.

出版信息

Blood. 1997 Jun 1;89(11):3919-24.

PMID:9166828
Abstract

We have previously reported the development of in vivo functional assays for primitive human hematopoietic cells based on their ability to repopulate the bone marrow (BM) of severe combined immunodeficient (SCID) and nonobese diabetic/SCID (NOD/SCID) mice following intravenous transplantation. Accumulated data from gene marking and cell purification experiments indicate that the engrafting cells (defined as SCID-repopulating cells or SRC) are biologically distinct from and more primitive than most cells that can be assayed in vitro. Here we demonstrate through limiting dilution analysis that the NOD/SCID xenotransplant model provides a quantitative assay for SRC. Using this assay, the frequency of SRC in cord blood (CB) was found to be 1 in 9.3 x 10(5) cells. This was significantly higher than the frequency of 1 SRC in 3.0 x 10(6) adult BM cells or 1 in 6.0 x 10(6) mobilized peripheral blood (PB) cells from normal donors. Mice transplanted with limiting numbers of SRC were engrafted with both lymphoid and multilineage myeloid human cells. This functional assay is currently the only available method for quantitative analysis of human hematopoietic cells with repopulating capacity. Both CB and mobilized PB are increasingly being used as alternative sources of hematopoietic stem cells in allogeneic transplantation. Thus, the findings reported here will have important clinical as well as biologic implications.

摘要

我们之前曾报道过,基于原始人类造血细胞在静脉移植后重建造血功能不全(SCID)和非肥胖糖尿病/ SCID(NOD / SCID)小鼠骨髓(BM)的能力,开发了体内功能检测方法。基因标记和细胞纯化实验积累的数据表明,植入细胞(定义为SCID重建造血细胞或SRC)在生物学上与大多数可在体外检测的细胞不同,且更为原始。在此,我们通过有限稀释分析证明,NOD / SCID异种移植模型为SRC提供了一种定量检测方法。使用该检测方法,发现脐带血(CB)中SRC的频率为每9.3×10⁵个细胞中有1个。这显著高于成年骨髓细胞中每3.0×10⁶个细胞中有1个SRC的频率,或正常供体动员外周血(PB)细胞中每6.0×10⁶个细胞中有1个SRC的频率。移植有限数量SRC的小鼠植入了淋巴样和多谱系髓样人类细胞。这种功能检测方法是目前唯一可用于定量分析具有重建造血能力的人类造血细胞的方法。在同种异体移植中,脐带血和动员外周血越来越多地被用作造血干细胞的替代来源。因此,此处报道的研究结果将具有重要的临床和生物学意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验